| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 06/02/2009 | CA2344290C Quinazoline derivatives |
| 06/02/2009 | CA2340416C Co-lyophilized complex of a nucleic acid vector and a formulating agent |
| 06/02/2009 | CA2339089C Cold-adapted equine influenza viruses |
| 06/02/2009 | CA2309104C Metal/thiol biocides |
| 06/02/2009 | CA2304950C Acidic aqueous chlorite teat dip providing shelf life, sanitizing capacity and tissue protection |
| 06/02/2009 | CA2274495C Uspa1 and uspa2 antigens of moraxella catarrhalis |
| 06/02/2009 | CA2258539C Ring-fused dihydropyranes, process for the preparation and use thereof |
| 06/02/2009 | CA2247388C Pharmaceutical composition comprising serum amyloid p component for prophylactic or therapeutic treatment of virus infections and a kit for detecting binding of compositions to virus components |
| 06/02/2009 | CA2211802C Pharmaceutical composition for the treatment of herpes |
| 05/28/2009 | WO2009067692A1 Antibacterial aminoglycoside analogs |
| 05/28/2009 | WO2009067630A1 2-amino purine derivatives and their use as anti-herpetic agents |
| 05/28/2009 | WO2009067541A2 Integrase inhibitors |
| 05/28/2009 | WO2009067409A1 2',4'-substituted nucleosides as antiviral agents |
| 05/28/2009 | WO2009067392A1 Cyclopropyl fused indolobenzazepine derivatives for the treatment of hepatitis c |
| 05/28/2009 | WO2009067166A2 Non-nucleoside reverse transcriptase inhibitors |
| 05/28/2009 | WO2009067108A1 Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors |
| 05/28/2009 | WO2009067081A1 Pyrimidine derivatives for the treatment of asthma, copd, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, cancer, hepatitis b, hepatitis c, hiv, hpv, bacterial infections and dermatosis |
| 05/28/2009 | WO2009066775A1 Amorphous form of heterocyclic compound, solid dispersion and medicinal preparation each comprising the same, and process for production of the same |
| 05/28/2009 | WO2009066702A1 Anti-hiv monoclonal antibody |
| 05/28/2009 | WO2009066655A1 Human antibody capable of inducing apoptosis |
| 05/28/2009 | WO2009066117A1 Use of edta and its derivatives for prevention and treatment of bacterial intestinal diseases of pigs and for increasing the effects of antibiotics exerted in such diseases |
| 05/28/2009 | WO2009065947A2 Pharmaceutical composition containing a zeolite/algae or zeolite/emulsion combination for the treatment of aids |
| 05/28/2009 | WO2009065893A1 New human papilloma virus inhibitors and pharmaceutical compositions containing same |
| 05/28/2009 | WO2009065787A1 Use of amorolfine for treating a nail disease by iontophoresis |
| 05/28/2009 | WO2009047534A3 Fused phenothiazinium compounds, preparation method thereof and use as photoantimicrobials |
| 05/28/2009 | WO2009046880A3 Use of a peptide as a therapeutic agent |
| 05/28/2009 | WO2009046858A3 Therapeutic uses of kisspeptin 13 and compositions thereof |
| 05/28/2009 | WO2009046822A3 Use of the peptide ymdgtmsqv as a therapeutic agent |
| 05/28/2009 | WO2009043527A3 Therapeutic use of human growth hormone 1-43 |
| 05/28/2009 | WO2009043521A3 Use of urocortin iii and urocortin i as therapeutic agents |
| 05/28/2009 | WO2009043506A3 Use of a peptide as a therapeutic agent |
| 05/28/2009 | WO2009043456A3 Use of a peptide as a therapeutic agent |
| 05/28/2009 | WO2009043155A3 Distinct hiv-1 gag and env epitopes of hla alleles associated with differential susceptibility to hiv-1 infection |
| 05/28/2009 | WO2009040051A3 Use of the peptide rfmwmk alone or in combination with the peptide ymdgtmsqv as a therapeutic agent |
| 05/28/2009 | WO2009040023A3 Use of galnon as a therapeutic agent |
| 05/28/2009 | WO2009040005A3 Use of the peptide rfmwmr as a therapeutic agent |
| 05/28/2009 | WO2009039985A3 Therapeutic uses of urocortin ii |
| 05/28/2009 | WO2009039984A3 Therapeutic uses of urocortin ii and kisspeptin ( 27-54 ) |
| 05/28/2009 | WO2009039983A3 Use of a peptide as a therapeutic agent |
| 05/28/2009 | WO2009033747A3 Use of a peptide as a therapeutic agent |
| 05/28/2009 | WO2009033660A3 Use of octreotide as a therapeutic agent |
| 05/28/2009 | WO2009029384A3 Compounds for the treatment of hepatitis c |
| 05/28/2009 | WO2008156610A3 Antibiotic compounds |
| 05/28/2009 | US20090137845 Novel 4-Dedimethylaminotetracycline derivatives |
| 05/28/2009 | US20090137818 Crystal structure of human coronavirus 229E main proteinase and uses for developing SARS inhibitors |
| 05/28/2009 | US20090137788 Nucleotide sequences coding bacterial cell surface proteins for use in generating monoclonal antibodies for prevention and treatment of infection |
| 05/28/2009 | US20090137778 A HIV peptide consisting of 23 to 50 amino acid residues; trans-activator |
| 05/28/2009 | US20090137666 FLUORESCENT PARTICLES COMPRISING NANOSCALE ZnO LAYER AND EXHIBITING CELL-SPECIFIC TOXICITY |
| 05/28/2009 | US20090137622 Use of pyrroloquinoline compounds to kill clinically latent microorganisms |
| 05/28/2009 | US20090137601 L-Phenylalanine Derivatives |
| 05/28/2009 | US20090137568 Tryclic Nitrogen Containing Compounds and their Use as Antibacterials |
| 05/28/2009 | US20090137553 Thiazepine Oxazolidinones as Antibacterial Agents |
| 05/28/2009 | US20090137533 Convenience Kit for Eyelid Treatment |
| 05/28/2009 | US20090137513 RNA Interference Mediated Inhibition of Acetyl-CoA-Carboxylase Gene Expression Using Short Interfering Nucleic Acid (siNA) |
| 05/28/2009 | US20090137512 nucleotide sequence complementary to a target RNA sequence and a second sequence chemically modified so it can no longer act as a guide sequence for mediating RNA interference, having complementarity to said first sequence; cancer, proliferative diseases |
| 05/28/2009 | US20090137511 RNA INTERFERENCE MEDIATED INHIBITION OF PLACENTAL GROWTH FACTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 05/28/2009 | US20090137509 RNA INTERFERENCE MEDIATED INHIBITION OF PROLIFERATION CELL NUCLEAR ANTIGEN (PCNA) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 05/28/2009 | US20090137508 Treatment of any disease that responds to modulation of gene expression, for example cancer, proliferative, inflammatory, metabolic, autoimmune, neurologic, ocular diseases; in vivo stability and bioavailability |
| 05/28/2009 | US20090137501 Resistance Genes |
| 05/28/2009 | US20090137495 Organic Compounds and Their Uses |
| 05/28/2009 | US20090137481 Antimicrobial polypeptides |
| 05/28/2009 | US20090137460 Cross-linked glycopeptide-cephalosporin antibiotics |
| 05/28/2009 | US20090136970 Nogo receptor homologues and their use |
| 05/28/2009 | US20090136603 Active component fraction of high antiviral activity |
| 05/28/2009 | US20090136570 Taste-Masked Tablets and Granules |
| 05/28/2009 | US20090136564 Micelles |
| 05/28/2009 | US20090136547 Zwitterionization of capsular saccharides |
| 05/28/2009 | US20090136541 Immunogenic composition |
| 05/28/2009 | US20090136539 Methods for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes, conjugated fatty acids, and/or conjugated fatty alcohols |
| 05/28/2009 | US20090136536 Recombinant Subunit Vaccine |
| 05/28/2009 | US20090136518 Compositions and methods to reduce mutagenesis |
| 05/28/2009 | US20090136515 Methods of diagnosing, preventing and treating infection with Hepatitis C virus |
| 05/28/2009 | US20090136484 Novel antibody molecules and nucleic acids |
| 05/28/2009 | US20090136448 Antiviral 2-Carboxy-Thiophene Compounds |
| 05/28/2009 | US20090136419 parenterally administering a dose of samarium ethylenediaminetetramethylenephosphonic acid (EDTMP); and carboplatin or taxoids; anticarcinogenic, antitumor, and antantiproliferative agents; autoimmune, infectious , metabolic or genetic disorders |
| 05/28/2009 | DE102007056253A1 Use of homogenized sloe composition, obtained by heating, e.g. for liquefaction of body fluids, reduction of surface tension, for the reduction of body odor, preferably excrement and sweat, to promote hair growth and as antibiotic |
| 05/28/2009 | CA2706536A1 Amorphous body composed of heterocyclic compound, solid dispersion and pharmaceutical preparation each comprising the same, and process for production of the same |
| 05/28/2009 | CA2706369A1 Antibacterial aminoglycoside analogs |
| 05/28/2009 | CA2706327A1 2',4'-substituted nucleosides as antiviral agents |
| 05/28/2009 | CA2706201A1 Peptides with capacity to bind to scurfin and applications |
| 05/28/2009 | CA2705944A1 Methods and compositions for inhibiting integrins using tellurium-containing compounds |
| 05/28/2009 | CA2705834A1 Non-nucleoside reverse transcriptase inhibitors |
| 05/28/2009 | CA2705662A1 New human papilloma virus inhibitors and pharmaceutical compositions containing same |
| 05/28/2009 | CA2704882A1 Use of amorolfine for treating a nail disease by iontophoresis |
| 05/28/2009 | CA2704214A1 Pyrimidine derivatives for the treatment of asthma, copd, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, cancer, hepatitis b, hepatitis c, hiv, hpv, bacterial infections and dermatosis |
| 05/27/2009 | EP2062972A1 Novel vaccine for dog |
| 05/27/2009 | EP2062884A1 Novel phenylacetic acid derivative |
| 05/27/2009 | EP2062879A1 Heterocyclic inhibitors of p38 |
| 05/27/2009 | EP2062595A1 Inhibition of inflammation using alpha 7 receptor-binding cholinergic agonists |
| 05/27/2009 | EP2062590A1 Peptide derived from Hepatitis C virus |
| 05/27/2009 | EP2062585A1 The antibiotics composition comprising aminoglycoside antibiotics |
| 05/27/2009 | EP2062583A2 Therapeutic applications of pro-apoptotic benzodiazepines |
| 05/27/2009 | EP2062582A1 The antibiotics composition comprising beta-lactam antibiotics and buffers |
| 05/27/2009 | EP2062581A1 The antibiotics composition comprising beta-lactam antibiotics and ionic chelating agents |
| 05/27/2009 | EP2062578A1 Novel use of chemical compounds for the treatment of AIDS |
| 05/27/2009 | EP2061808A1 Influenza antibodies, compositions, and related methods |
| 05/27/2009 | EP2061805A1 Recombinant hcv e2 glycoprotein |
| 05/27/2009 | EP2061513A1 Method of treating hepatitis c patients |
| 05/27/2009 | EP2061505A2 Composition for eliciting a specific ctl response, comprising a lympho-ablative compound and a molecule that contains antigenic sequences and targets professional antigen presenting cells |
| 05/27/2009 | EP2061490A1 Modulators of candida hyphal morphogenesis and uses thereof |